 Isabel Griffin, PhD, MPH^a, Stephanie A. Irving, MHS^b, Carmen Sofia Arriola, PhD^a, Angela F Campbell, MD, MPH^a, De-Kun Li, MD, PhD^c, Fatimah S. Dawood, MD^a, Caroline Doughty- Skierski^d, Jeannette R. Ferber, MPH^c, Nickolas Ferguson^e, Louise Hadden^e, Jillian T. Henderson^b, Mary Juergens^e, Venkatesh Kancharla^d, Allison L. Naleway^b, Gabriella Newes- Adeyi^e, Erin Nicholson^d, Roxana Odouli, MSPH^c, Lawrence Reichle^e, Mo Sanyang^d, Kate Woodworth, MD, MPH^a, Flor M. Munoz^d Affiliations: ^aCenters for Disease Control and Prevention, Atlanta, Georgia; and ^bCenter for Health Research, Kaiser Permanente Northwest, Portland, Oregon; and ^cKaiser Permanente Northern California, Oakland, California; and ^dBaylor College of Medicine, Houston, Texas; and
 Isabel Griffin, PhD, MPH^a, Stephanie A. Irving, MHS^b, Carmen Sofia Arriola, PhD^a, Angela F Campbell, MD, MPH^a, De-Kun Li, MD, PhD^c, Fatimah S. Dawood, MD^a, Caroline Doughty- Skierski^d, Jeannette R. Ferber, MPH^c, Nickolas Ferguson^e, Louise Hadden^e, Jillian T. Henderson^b, Mary Juergens^e, Venkatesh Kancharla^d, Allison L. Naleway^b, Gabriella Newes- Adeyi^e, Erin Nicholson^d, Roxana Odouli, MSPH^c, Lawrence Reichle^e, Mo Sanyang^d, Kate Woodworth, MD, MPH^a, Flor M. Munoz^d Affiliations: ^aCenters for Disease Control and Prevention, Atlanta, Georgia; and ^bCenter for Health Research, Kaiser Permanente Northwest, Portland, Oregon; and ^cKaiser Permanente Northern California, Oakland, California; and ^dBaylor College of Medicine, Houston, Texas; and
 Campbell, MD, MPH^a, De-Kun Li, MD, PhD^c, Fatimah S. Dawood, MD^a, Caroline Doughty- Skierski^d, Jeannette R. Ferber, MPH^c, Nickolas Ferguson^e, Louise Hadden^e, Jillian T. Henderson^b, Mary Juergens^e, Venkatesh Kancharla^d, Allison L. Naleway^b, Gabriella Newes- Adeyi^e, Erin Nicholson^d, Roxana Odouli, MSPH^c, Lawrence Reichle^e, Mo Sanyang^d, Kate Woodworth, MD, MPH^a, Flor M. Munoz^d Affiliations: ^aCenters for Disease Control and Prevention, Atlanta, Georgia; and ^bCenter for Health Research, Kaiser Permanente Northwest, Portland, Oregon; and ^cKaiser Permanente Northern California, Oakland, California; and
 Skierski^d, Jeannette R. Ferber, MPH^c, Nickolas Ferguson^e, Louise Hadden^e, Jillian T. Henderson^b, Mary Juergens^e, Venkatesh Kancharla^d, Allison L. Naleway^b, Gabriella Newes- Adeyi^e, Erin Nicholson^d, Roxana Odouli, MSPH^c, Lawrence Reichle^e, Mo Sanyang^d, Kate Woodworth, MD, MPH^a, Flor M. Munoz^d Affiliations: ^aCenters for Disease Control and Prevention, Atlanta, Georgia; and ^bCenter for Health Research, Kaiser Permanente Northwest, Portland, Oregon; and ^cKaiser Permanente Northern California, Oakland, California; and
 Henderson^b, Mary Juergens^e, Venkatesh Kancharla^d, Allison L. Naleway^b, Gabriella Newes- Adeyi^e, Erin Nicholson^d, Roxana Odouli, MSPH^c, Lawrence Reichle^e, Mo Sanyang^d, Kate Woodworth, MD, MPH^a, Flor M. Munoz^d Affiliations: ^aCenters for Disease Control and Prevention, Atlanta, Georgia; and ^bCenter for Health Research, Kaiser Permanente Northwest, Portland, Oregon; and ^cKaiser Permanente Northern California, Oakland, California; and
 Adeyi^e, Erin Nicholson^d, Roxana Odouli, MSPH^c, Lawrence Reichle^e, Mo Sanyang^d, Kate Woodworth, MD, MPH^a, Flor M. Munoz^d Affiliations: ^aCenters for Disease Control and Prevention, Atlanta, Georgia; and ^bCenter for Health Research, Kaiser Permanente Northwest, Portland, Oregon; and ^cKaiser Permanente Northern California, Oakland, California; and ^dBaylor College of Medicine, Houston, Texas; and
 8 Woodworth, MD, MPH^a, Flor M. Munoz^d 9 10 Affiliations: 11 ^aCenters for Disease Control and Prevention, Atlanta, Georgia; and 12 ^bCenter for Health Research, Kaiser Permanente Northwest, Portland, Oregon; and 13 ^cKaiser Permanente Northern California, Oakland, California; and 14 ^dBaylor College of Medicine, Houston, Texas; and
 Affiliations: ^aCenters for Disease Control and Prevention, Atlanta, Georgia; and ^bCenter for Health Research, Kaiser Permanente Northwest, Portland, Oregon; and ^cKaiser Permanente Northern California, Oakland, California; and ^dBaylor College of Medicine, Houston, Texas; and
 Affiliations: ^aCenters for Disease Control and Prevention, Atlanta, Georgia; and ^bCenter for Health Research, Kaiser Permanente Northwest, Portland, Oregon; and ^cKaiser Permanente Northern California, Oakland, California; and ^dBaylor College of Medicine, Houston, Texas; and
 ^aCenters for Disease Control and Prevention, Atlanta, Georgia; and ^bCenter for Health Research, Kaiser Permanente Northwest, Portland, Oregon; and ^cKaiser Permanente Northern California, Oakland, California; and ^dBaylor College of Medicine, Houston, Texas; and
 Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon; and ^cKaiser Permanente Northern California, Oakland, California; and ^dBaylor College of Medicine, Houston, Texas; and
 ¹³ Kaiser Permanente Northern California, Oakland, California; and ¹⁴ ^dBaylor College of Medicine, Houston, Texas; and
14 Baylor Conege of Medicine, Houston, Texas, and
15 ^c Abt Associates Inc Pockwille MD
15 Abi Associates, inc, Rockvine, MD
17
18 Address correspondence to: Carmen Sofia Arriola, Influenza Division, Centers for Disease
19 Control and Prevention, 1600 Clifton Rd MS A-32, Atlanta, GA 30329, United States;
20 telephone: (404) 718-4589; fax (404) 639-3866; email: wus3@cdc.gov.
21
22 Short title: Incidence Rates of COVID-19 in Infants
23
24 Conflict of Interest Disclosures (includes financial disclosures): Author A. Naleway reports
25 institutional support from Pfizer and Vir Biotechnology. All other authors have indicated that
they have no conflicts of interest or financial relationships relevant to this article to disclose.
28 Other Disclosures: The findings and conclusions in this report are those of the authors and do
²⁹ not necessarily represent the official position of the Centers for Disease Control and Prevention
30 (CDC).
Funding/Support . This study was funded by the US Centers for Disease Control and
33 Prevention (CDC) through Contract # 75D30120C08150 with Abt Associates
34
Role of Funder/Sponsor: This study was funded by the US Centers for Disease Control and
36 Prevention (CDC). CDC-affiliated authors were involved in study design, data collection,
analysis and interpretation, report writing, and the decision to submit the paper for
publication. The corresponding author had full access to all data used in the analysis and had
39 final responsibility for the decision to submit for publication.
40
41 Abbreviations: COVID-19— coronavirus disease 2019, SARS-CoV-2 – severe acute
42 respiratory syndrome coronavirus 2, RT-PCR—Reverse Transcription Polymerase Chain
43 Reaction.
44

Article Summary This report describes incidence rates and characteristics of medically attended outpatient and inpatient COVID-19 episodes among infants aged <6 months during the COVID-19 pandemic. What's Known on This Subject Surveillance data and case series suggest that infants aged <1 year may be more likely to be hospitalized with COVID-19 than older children, but few data are available about the risk of medically attended COVID-19 episodes among infants. What this Study Adds Among infants aged <6 months, few were hospitalized with COVID-19. Incidence rates of medically attended COVID-19 episodes were highest among infants aged ≤ 1 month and among infants of women with COVID-19 during the 6 month post-partum period. **Contributors' Statement Page** Dr. Dawood, Dr. Arriola, Dr Campbell, Dr Li, Dr Henderson, Ms. Irving, Dr. Naleway, Dr. Munoz, and Dr. Nicholson conceptualized and designed the study and data collection procedures. Dr. Woodworth conceptualized and designed the analysis, drafted the initial manuscript, and reviewed and revised the manuscript. Dr. Griffin conceptualized and designed the analysis, carried out all analyses, drafted the initial manuscript, and reviewed and revised the manuscript. Ms. Doughty-Skierski, Ms. Ferber, Mr. Kancharla, Ms. Irving, Ms. Odouli, Mr Sanyang, Dr. Newes-Adeyi, Ms. Juergens, Mr. Ferguson, Ms. Hadden and Mr. Reichle collected data and provided data for this analysis. All authors critically reviewed and revised the manuscript, approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

92 Abstract

93

94 **Objective**

- 95 Studies suggest infants may be at increased risk of severe COVID-19 relative to older children,
- but few data exist regarding the incidence of COVID-19 episodes and associated risk factors. We
- 97 estimate incidence rates and describe characteristics associated with medically attended COVID-
- 98 19 episodes among infants younger than 6 months of age.
- 99

100 Methods

- 101 We analyzed electronic medical record data from a cohort of infants born March 1, 2020–
- 102 February 28, 2021. Data from three health care delivery systems included demographic
- 103 characteristics, maternal and infant outpatient visit and hospitalization diagnoses, and SARS-
- 104 CoV-2 test results. Medically attended COVID-19 episodes were defined by positive SARS-
- 105 CoV-2 clinical tests and/or COVID-19 diagnosis codes during medical care visits. Unadjusted
- and site-adjusted incidence rates by infant month of age, low and high SARS-CoV-2 circulation
- 107 periods and maternal COVID-19 diagnosis were calculated.
- 108

109 **Results**

Among 18,192 infants aged <6 months whose mothers received prenatal care within the three systems, 173 (1.0%) had medically attended COVID-19 episodes. Incidence rates were highest among infants aged under 1 month (2.0 per 1,000 person-weeks) and 1 month (2.0 per 1,000 person-weeks) compared with older infants. Incidence rates were also higher for infants born to women with postpartum COVID-19 compared with women without known COVID-19 and women diagnosed with COVID-19 during pregnancy.

116117 Conclusion

118 Most medically attended COVID-19 episodes in infants aged <6 months were outpatient care 119 encounters. Infants of women with postpartum COVID-19 had a higher risk of medically attended 120 COVID-19 than infants born to mothers who were diagnosed during pregnancy or never diagnosed 121 underscoring the importance of COVID-19 prevention measures for their household members and

- 122 caregivers to prevent infections in infants.
- 123

124

- 125 Early in the coronavirus disease 2019 (COVID-19) pandemic, surveillance data
- suggested that COVID-19 was infrequent and mild in children but that hospitalization rates
- among infants aged <1 year might be higher than among older children.¹ More recent studies
- suggest that infants aged less than one year of age primarily experience mild to moderate
- 129 COVID-19, but represent a disproportionate amount of pediatric COVID-19 associated
- hospitalizations.^{2,3,4,5,6} However, most published studies to date describing severe acute

respiratory syndrome-related coronavirus (SARS-CoV-2) infection among infants are based on 131 convenience samples with small numbers of infants that preclude examining outcomes by age 132 133 group and lack population denominators that allow an assessment of true community risk. Estimates of incidence rates of medically attended COVID-19 episodes among infants, including 134 135 outpatient care encounters, could help guide risk communication for expectant and new parents 136 and might inform future public health recommendations for this group. The Epidemiology of SARS-CoV-2 in Pregnancy and Infancy (ESPI) Network: Electronic 137 Cohort (eESPI) collected electronic medical record data for a retrospective cohort of pregnant 138 139 persons and their infants who were born during the COVID-19 pandemic. Data about infants were 140 collected up until the date they turned six months old. We analyzed data from the eESPI pregnancy and infant cohort to describe infants <6 months of age with and without medically attended 141 COVID-19 episodes including both hospitalizations and outpatient care encounters (including 142 urgent care and emergency department encounters). Additionally, we estimated incidence rates of 143 144 medically attended COVID-19 episodes overall and by level of SARS-CoV-2 circulation, site, age

146

145

147 METHODS

148 <u>Study design and population</u>

The eESPI study was conducted at three healthcare delivery systems in the United States: Kaiser Permanente Northwest (Portland, OR), Kaiser Permanente Northern California (Oakland, CA), and Baylor College of Medicine (Houston, TX). Persons were eligible for inclusion in the maternal cohort if they 1) had an estimated delivery date (EDD) from March 1, 2020 through February 28, 2021 excluding women with pregnancy losses that occurred prior to March 1, 2020

group, and maternal COVID-19 diagnosis during pregnancy and the six month postpartum period.

154	and 2) had at least one prenatal care outpatient or telemedicine visit within the respective health
155	system from December 1, 2019 through February 28, 2021. The infant cohort included all live
156	born infants of individuals included in the maternal cohort. This analysis included all infants
157	born from March 1, 2020 through February 28, 2021.
158	Data collection
159	Data were extracted from electronic medical records using standardized variable
160	definitions across study sites (see Supplemental Methods Data Dictionary – Appendix A and
161	Appendix B). Most variables were defined by one or more International Classifications of
162	Diseases 10 (ICD-10) codes. Data collection included maternal and infant demographic
163	characteristics, maternal prenatal visit history, maternal and infant medical conditions, diagnosis
164	codes for all telemedicine, emergency department (ED), and ambulatory care encounters and
165	hospitalizations, and results from all SARS-CoV-2 RT-PCR testing. For this study, data about
166	infants were collected from birth until they turned six months of age or their age as of February
167	28, 2021, whichever occurred first.
168	Analysis definitions

All variables derived from ICD-10 codes can be found in Appendix A and Appendix B. Medically attended COVID-19 episodes in infants, including telemedicine, ED, and ambulatory care encounters, were identified based on at least one of the following: 1) a positive RT-PCR test for SARS-CoV-2 within three days of a medical encounter, or 2) a COVID-19 diagnostic code (ICD-10: U07.1) (Appendix A). Hospitalizations for any reason were counted if they met the test and diagnostic criteria described above.

5

Maternal race/ethnicity was extracted from electronic medical records and classified as 175 Hispanic/Latina, non-Hispanic White, non-Hispanic Black, and non-Hispanic Other. The non-176 Hispanic Other race/ethnicity category included American Indian or Alaska Native, Asian, 177 Native Hawaiian or Pacific Islander, and women who had more than one race listed in their 178 medical record. A list of conditions determined to be underlying medical conditions for mothers 179 180 and infants can be found in the Supplemental Methods Data Dictionary (Appendix B). Timing of underlying medical conditions for infants was based on timing relative to any COVID-19 181 182 diagnosis or positive test. Timing of COVID-19 for mothers was determined based on either a 183 documented positive RT-PCR or antigen test for SARS-CoV-2 or COVID-19 diagnostic code during pregnancy or during the postpartum period (two mothers had COVID-19 documented 184 during both pregnancy and the postpartum period). The postpartum period was defined as the six 185 186 months immediately following delivery. Gestational age at delivery (preterm [<37 weeks] or term/post-term [≥37 weeks]) was 187 determined using reported gestational age at delivery or derived from delivery date and estimated 188 189 date of conception (Appendix A). High and low SARS-CoV-2 circulation weeks were defined 190 for each site as weeks with case counts above the median case count (high) or below the median 191 case count (low) for the study period, using Health and Human Services (HHS) representative county-level surveillance data for Texas (Harris County), Oregon (Multnomah County), and 192 California (Santa Clara County) in each health system's service area.⁷ 193

194

195 <u>Analysis</u>

6

Frequencies of maternal and infant characteristics were described for infants with and without medically attended COVID-19 episodes. Available characteristics of interest included maternal race/ethnicity, maternal Medicaid status, maternal COVID-19 diagnosis (during pregnancy, during the six month postpartum period, or both during pregnancy and the postpartum period), gestational age at birth, infant sex, presence of any underlying medical conditions for mother and infant, and site. Unadjusted chi-square and fisher's exact test p-values of ≤ 0.05 were considered statistically significant.

203 For incidence rate calculations, an aggregate crude incidence rate for the full cohort was 204 calculated with the total number of infants with medically attended COVID-19 episodes as the numerator and the total number of person-weeks at risk that each infant (those with and without 205 medically attended COVID-19 episodes) was in the cohort as the denominator. Site-adjusted 206 negative binomial models were then used to estimate incidence per 1,000 person-weeks and 207 95% confidence intervals by infant sex, maternal race/ethnicity, maternal Medicaid status, 208 209 presence of any underlying medical conditions for mother and infant, age in months (<1 month, 1 month, 2 months, 3 months, 4 months, and 5 months of age), maternal SARS-CoV-2 infection 210 status (no infection, infection during pregnancy or infection during the six-month postpartum 211 212 period), and low or high SARS-CoV-2 circulation in the community.

All analyses were conducted in SAS Version 9.4.

214 <u>Ethical Review</u>

This protocol was reviewed by the Institutional Review Boards of participating sites. This
activity was reviewed by CDC and was conducted consistent with applicable federal law and
CDC policy.

218

219 RESULTS

Among 18,192 infants aged less than six months of age in the cohort, 173 (1.0%) had 220 221 medically attended COVID-19 episodes, including 114 (65.9%) identified by positive SARS-CoV-222 2 laboratory testing and 59 (34.1%) by COVID-19 diagnosis code only without a documented laboratory-test in the medical record. Medically attended COVID-19 episodes were more frequent 223 224 among infants from site B (1.4% of 7,434 infants) compared with those from sites A and C (site A 225 0.8% of 4,794 infants and site C 0.5% of 5,964 infants) (Table 1). There were no differences between infants with versus without medically attended COVID-19 episodes by infant sex or 226 gestational age at birth. However, compared to infants without medically attended COVID-19, a 227 larger proportion of infants with medically attended COVID-19 episodes were infants of Hispanic 228 229 mothers (46.8% vs. 27.9%, <0.0001), Medicaid beneficiaries (29.5% vs. 22.4%, p=0.05), and 230 mothers with postpartum COVID-19 (57.2% vs. 1.5%, $p \le 0.0001$). Of the 173 infants with medically attended COVID-19 episodes, 27 (15.6%) were diagnosed at <1 month of age, 29 231 232 (16.7%) at 1 month of age, 28 (16.2%) at 2 months, 16 (9.2%) at 3 months, 31 (17.9%) at 4 months, and 42 (24.3%) at 5 months of age. A larger proportion of infants with medically attended COVID-233 19 episodes also had any underlying medical condition (12.1% vs. 7.3%, p=0.02). Six of 173 234 235 infants with medically attended COVID-19 (3.5%) had an underlying heart-related condition, 11 (6.4%) had an underlying lung-related condition, and 1 (0.6%) had a liver-related condition 236 (Appendix A); all conditions were documented prior to or on the same days as the infant's COVID-237 19 diagnosis or positive SARS-CoV-2 test result. 238

Among the 173 infants with medically attended COVID-19 episodes, 148 (85.6%) were first diagnosed in association with telemedicine visits, 20 (11.6%) during ambulatory/outpatient visits, one (0.6%) during an emergency room visit, and four (2.3%) during hospitalization (data

not shown). All four hospitalizations occurred among infants aged 0-1 month. Hospital lengths of
stay ranged from 2-5 days, and none included intensive care unit admission, mechanical
ventilation, or extracorporeal membrane oxygenation.

245

246 Incidence of Medically Attended COVID-19 Episodes

247 The overall cumulative incidence of medically attended COVID-19 episodes was 0.95%. The aggregate crude incidence rate among the full cohort was 0.6 per 1,000 person-weeks. Site-248 249 adjusted incidence rates of medically attended COVID-19 episodes varied by local SARS-CoV-2 250 COVID-19 circulation (high versus low), infant age, maternal race/ethnicity, maternal Medicaid status, infant underlying conditions, and maternal COVID-19 diagnosis (Table 2). The overall site-251 adjusted incidence rates of medically attended COVID-19 episodes were 0.6 per 1,000 person-252 253 weeks during high SARS-CoV-2 circulation periods and 0.4 per 1,000 person-weeks during low 254 circulation periods. By infant age, the site-adjusted incidence rates of medically attended COVID-255 19 episode were highest among infants under 1 month and 1 month of age (2.0 and 2.0 per 1,000 person-weeks, respectively) compared with older infants. 256

Infants born to mothers with COVID-19 diagnosed during the six-month postpartum period had a higher incidence rate of medically attended COVID-19 episodes (12.5 per 1,000 personweeks) than infants born to mothers diagnosed with COVID-19 during pregnancy alone (0.5 per 1,000 person-weeks) and compared to infants born to mothers who were never diagnosed with COVID-19 during pregnancy or the postpartum period (0.2 per 1,000 person-weeks).

262

263 DISCUSSION

Among a cohort of >18,000 infants born during the first year of the COVID-19 pandemic 264 in the United States and followed up to six months of age, the overall cumulative incidence of 265 medically attended COVID-19 episodes was 0.95%. Incidence rates varied by level of community 266 transmission, maternal COVID-19 status, maternal race/ethnicity, and infant month of age. The 267 majority of medically attended COVID-19 episodes were outpatient encounters, largely 268 269 comprising telemedicine visits, and only four infants (<0.1% of the cohort) during their first month 270 of life had COVID-19 associated hospitalizations. Findings from this analysis provide reassurance 271 that the overall risk of medically attended COVID-19 episodes among young infants was low 272 during the study period, which preceded the emergence of both the Delta and Omicron variants, and risk of COVID-19-associated hospitalizations was very low for this group. Incidence rates of 273 medically attended COVID-19 episodes were higher among infants of women with COVID-19 274 275 diagnosed during the six-month postpartum period compared to infants born to mothers diagnosed 276 at other times or never diagnosed suggesting potential horizontal transmission between mother and 277 infant and increasing opportunities for community acquisition with increasing infant age. This finding underscores the importance of COVID-19 prevention measures for household members 278 and caregivers of young infants to reduce transmission to young infants. In addition, the highest 279 280 incidence rates of medically attended COVID-19 episodes were among infants born to Hispanic (0.9 per 1,000 person-weeks) and Non-Hispanic Black mothers (0.9 per 1,000 person-weeks) after 281 282 adjusting for study site, a finding consistent with those from other studies documenting disparities related to COVID-19 disease burden among minority populations during this study period.^{8,9,10,11} 283 284 Findings from this analysis suggest that the risk of medically attended COVID-19 episodes 285 among infants in the United States was low during the first year of the pandemic. We were not 286 able to assess the influence of community exposures or preventive practices on incidence rate of

medically attended COVID-19 episodes among young infants. However, our finding that incidence 287 rates of medically attended COVID-19 episodes were higher among infants of mothers diagnosed 288 with COVID-19 during the six-month postpartum period suggest that SARS-CoV-2 transmission 289 within households and from caregivers may be important sources of infection for young infants. 290 To reduce the risk of SARS-CoV-2 infection and subsequent medically attended COVID-19 291 292 episodes among infants, infection prevention counseling for families and caregivers of young 293 infants should include information about the importance of non-pharmaceutical prevention 294 measures such as handwashing and mask wearing and the benefits of COVID-19 vaccination 295 among eligible persons. Maternal COVID-19 vaccination (either during or prior to pregnancy) may decrease SARS-CoV-2 infection among infants by passive transfer of maternal antibodies to 296 infants and by preventing maternal infections during the postpartum period.^{12,13,14,15} Maternal 297 vaccination during pregnancy has an estimated 61% effectiveness against COVID-19 298 299 hospitalization in infants aged <6 months and maternal COVID-19 vaccination is recommended by both CDC and the American College of Obstetricians and Gynecologists (ACOG).^{16,17,18} Other 300 family members and caregivers should also be encouraged to receive COVID-19 vaccine to reduce 301 their risk of SARS-CoV-2 infection and subsequent transmission to young infants in their care. 302

Infants with medically attended COVID-19 episodes had more underlying medical conditions diagnosed during the first six months of life compared with infants without COVID-19, though this difference was small. This finding is consistent with the literature that found younger children with severe disease were more likely to have underlying conditions.^{5,19} This may be due to increased healthcare seeking behaviors among individuals with medical conditions that afford more opportunities to get SARS-CoV-2 testing.²⁰

This analysis has several limitations. First, medically attended COVID-19 episodes were 309 identified based on clinician-initiated testing and/or ICD-10 codes for COVID-19 which may have 310 311 led to under-ascertainment of episodes and/or differential detection of episodes among infants with different demographic or maternal characteristics. For example, infants of women with COVID-312 19 diagnosed during the postpartum period may have been more likely to be tested for SARS-313 314 CoV-2 because they had a known history of exposure to someone with COVID-19. Second, this analysis was based on data from the first year of the COVID-19 pandemic in the United States and 315 316 may not be fully generalizable to subsequent periods of SARS-CoV-2 circulation of emerging 317 variants during which younger pediatric age groups were increasingly impacted. Third, this analysis was not able to assess factors that may have led to differences in incidence rates of 318 medically attended COVID-19 episodes by site, such as differences in SARS-CoV-2 circulation 319 320 patterns, clinical testing practices, and demographic characteristics of the source population. Lastly, the analysis did not account for maternal COVID-19 vaccination status. However, the 321 322 frequency of women fully vaccinated in this cohort was likely low since women in this cohort were pregnant prior to April 2021 when COVID-19 vaccine became available to the general 323 population of adults <65 years of age in the United States.^{21,22} 324

325

326 CONCLUSIONS

Among a cohort of infants aged <6 months at three sites in the US during the first year of the COVID-19 pandemic, the incidence of medically attended COVID-19 episodes was low with outpatient care encounters accounting for the large majority of episodes. The highest incidence rates of medically attended COVID-19 episodes occurred among infants in the first two months of life and among infants of women diagnosed with COVID-19 during the postpartum period. These

- findings underscore the importance of COVID-19 prevention measures for pregnant women,
- household members, and families and caregivers of infants to protect infants who are too young to
- 334 receive COVID-19 vaccine.

Acknowledgements

We express our gratitude to the Epidemiology of SARS-CoV-2 in Pregnancy and Infancy (ESPI) Network: Electronic Cohort (eESPI) team for their tremendous effort in abstracting electronic health record data. The authors at KPNC thank Andrew K. Hirst for his help with programming and technical support, the authors at KPNW acknowledge Elizabeth Shuster and Jan Van Marter. The authors at Baylor College of Medicine acknowledge Nanette Bond and Patricia Santarcangelo. The authors at Abt Associates acknowledge Michael Duckworth and Peiyi Zhang. The authors from CDC acknowledge Michael Daugherty and Kellye Sliger for data management.

References

- 1. Dong Y, Mo X, Hu Y, et al. Epidemiology of COVID-19 Among Children in China. *Pediatrics*. 2020;145(6):e20200702. doi:10.1542/peds.2020-0702
- Liu X, Tang J, Xie R, et al. Clinical and Epidemiological Features of 46 Children <1 Year Old With Coronavirus Disease 2019 in Wuhan, China: A Descriptive Study [published correction appears in J Infect Dis. 2021 Feb 13;223(3):540]. *J Infect Dis*. 2020;222(8):1293-1297. doi:10.1093/infdis/jiaa472
- 3. Ouldali N, Yang D, Madhi F, et al. Factors Associated With Severe SARS-CoV-2 Infection. *Pediatrics*. 2021;147(3):e2020023432. doi:10.1542/peds.2020-023432
- 4. Neef V, Buxmann H, Rabenau H, Zacharowski K, Raimann F. Characterization of neonates born to mothers with SARS-CoV-2 infection: Review and meta-analysis. *Pediatr Neonatol.* 2021;62(1):11-20. doi:10.1016/j.pedneo.2020.10.001.
- Hobbs CV, Woodworth K, Young CC, et al. Frequency, Characteristics and Complications of COVID-19 in Hospitalized Infants. *Pediatr Infect Dis J*. 2022;41(3):e81-e86. doi:10.1097/INF.00000000003435
- 6. Woodruff RC, Campbell AP, Taylor CA, et al. Risk Factors for Severe COVID-19 in Children [published online ahead of print, 2021 Dec 22]. *Pediatrics*. 2021;e2021053418. doi:10.1542/peds.2021-053418
- Health and Human Services. Number of COVID-19 cases confirmed by U.S. county & State Health Departments by Report Week. Protect Public Data Hub 2021 [cited 2021 April 8]; Available from: <u>www.protect.hhs.gov</u>.
- Acosta AM, Garg S, Pham H, et al. Racial and Ethnic Disparities in Rates of COVID-19-Associated Hospitalization, Intensive Care Unit Admission, and In-Hospital Death in the United States From March 2020 to February 2021. *JAMA Netw Open*. 2021;4(10):e2130479. Published 2021 Oct 1. doi:10.1001/jamanetworkopen.2021.30479
- Centers for Disease Control and Prevention. COVID-19: Risk for COVID-19 Infection, Hospitalization, and Death by Race/Ethnicity. 2022 Feb 1 [cited 2022 March 9]; Available from: https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigationsdiscovery/hospitalization-death-by-race-ethnicity.html
- Jacobson M, Chang TY, Shah M, Pramanik R, Shah SB. Racial and Ethnic Disparities in SARS-CoV-2 Testing and COVID-19 Outcomes in a Medicaid Managed Care Cohort. *Am J Prev Med.* 2021;61(5):644-651. doi:10.1016/j.amepre.2021.05.015
- 11. Yehia BR, Winegar A, Fogel R, et al. Association of Race With Mortality Among Patients Hospitalized With Coronavirus Disease 2019 (COVID-19) at 92 US

Hospitals. *JAMA Netw Open*. 2020;3(8):e2018039. Published 2020 Aug 3. doi:10.1001/jamanetworkopen.2020.18039

- Rottenstreich A, Zarbiv G, Oiknine-Djian E, Zigron R, Wolf DG, Porat S. Efficient Maternofetal Transplacental Transfer of Anti- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Antibodies After Antenatal SARS-CoV-2 BNT162b2 Messenger RNA Vaccination. *Clin Infect Dis.* 2021;73(10):1909-1912. doi:10.1093/cid/ciab266
- Beharier O, Plitman Mayo R, Raz T, et al. Efficient maternal to neonatal transfer of antibodies against SARS-CoV-2 and BNT162b2 mRNA COVID-19 vaccine [published correction appears in J Clin Invest. 2021 Oct 1;131(19):]. J Clin Invest. 2021;131(13):e150319. doi:10.1172/JCI150319
- Collier AY, McMahan K, Yu J, et al. Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women. JAMA. 2021;325(23):2370-2380. doi:10.1001/jama.2021.7563
- 15. Mithal LB, Otero S, Shanes ED, Goldstein JA, Miller ES. Cord blood antibodies following maternal coronavirus disease 2019 vaccination during pregnancy. *Am J Obstet Gynecol.* 2021;225(2):192-194. doi:10.1016/j.ajog.2021.03.035
- 16. Halasa NB, Olson SM, Staat MA, et al. Effectiveness of Maternal Vaccination with mRNA COVID-19 Vaccine During Pregnancy Against COVID-19-Associated Hospitalization in Infants Aged <6 Months - 17 States, July 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022;71(7):264-270. Published 2022 Feb 18. doi:10.15585/mmwr.mm7107e3.
- 17. Centers for Disease Control and Prevention (CDC). National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases. COVID-19 Vaccines While Pregnant or Breastfeeding. December 6, 2021. Retrieved from: <u>https://www.cdc.gov/coronavirus/2019-</u> ncov/vaccines/recommendations/pregnancy.htmln on December 16, 2021.

 18. The American College of Obstetrics and Gynecologists. Practice Advisory: COVID-19 Vaccination Considerations for Obstetric–Gynecologic Care. 2021 Dec 3. [Cited: Dec 16 2021]. Retrieved from: <u>https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/12/covid-19-vaccination-considerations-for-obstetric-gynecologiccare on December 16, 2021.
</u>

- Kim L, Whitaker M, O'Halloran A, et al. Hospitalization Rates and Characteristics of Children Aged <18 Years Hospitalized with Laboratory-Confirmed COVID-19 -COVID-NET, 14 States, March 1-July 25, 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69(32):1081-1088. Published 2020 Aug 14. doi:10.15585/mmwr.mm6932e3
- 20. Lu P, Kong D, Shelley M. Risk Perception, Preventive Behavior, and Medical Care Avoidance among American Older Adults During the COVID-19 Pandemic. J Aging Health. 2021;33(7-8):577-584. doi:10.1177/08982643211002084
- 21. COVID Data Tracker: COVID-19 vaccination among pregnant people aged 18-49 years overall, by race/ethnicity, and date reported to CDC Vaccine Safety Datalink, United States. Centers for Disease Control and Prevention. Retrieved from: <u>https://covid.cdc.gov/covid-data-tracker/#vaccinations-pregnant-women</u> on January 11, 2022.
- 22. Razzaghi H, Meghani M, Pingali C, et al. COVID-19 Vaccination Coverage Among Pregnant Women During Pregnancy - Eight Integrated Health Care Organizations, United

States, December 14, 2020-May 8, 2021. *MMWR Morb Mortal Wkly Rep.* 2021;70(24):895-899. Published 2021 Jun 18. doi:10.15585/mmwr.mm7024e2

Table 1. Maternal and Infant Characteristics by whether Infants had Medically Attended Coronavirus Disease (COVID-19) Episodes before 6 Months of Age, Epidemiology of SARS-CoV-2 in Pregnancy and Infancy (ESPI) Network: Electronic Cohort (eESPI) (N= 18,192 infants).

	Total	Infants with	Infants without	P^{a}
	(N=18,192)	Medically	Medically	
		Attended	Attended	
		COVID-19	COVID-19	
		Episodes	Episodes	
	n	(n=173)	(n=18,019)	
Characteristics		n (row %)	n (row %)	
Study Site				< 0.0001
А	4794	38 (0.8)	4756 (99.2)	
В	7434	106 (1.4)	7328 (98.6)	
С	5964	29 (0.5)	5935 (99.5)	
Infant Sex				0.66
Male	9345	93 (1.0)	9252 (99.0)	
Female	8842	80 (0.9)	8762 (99.1)	
Unknown	5	0 (0.0)	5 (100)	
Maternal Race/Ethnicity ^b				< 0.0001

Non-Hispanic White	7583	32 (0.4)	7551 (99.6)	
Non-Hispanic Black	1871	25 (1.3)	1846 (98.7)	
Hispanic	5112	81 (1.6)	5031 (98.4)	
Other	3318	30 (0.9)	3288 (99.1)	
Unknown	308	5 (1.6)	303 (98.4)	
Maternal Medicaid				0.05
Yes	4085	51 (1.2)	4034 (98.8)	
No	13947	120 (0.9)	13827 (99.1)	
Unknown	160	2 (1.2)	158 (98.8)	
Maternal COVID-19				< 0.0001
Diagnosis ^c				
No Known COVID-19	17122	66 (0.4)	17056 (99.6)	
During Pregnancy only	623	6 (1.0)	617 (99.0)	
During Post-partum	367	99 (27.0)	268 (73.0)	
Period				
During Pregnancy and	80	2 (2.5)	78 (97.5)	
Post-partum Period				
Gestational Age at Birth ^d				0.31
Preterm (< 37 weeks)	1819	18 (1.0)	1801 (99.0)	
Term or Post-Term (≥37	16373	155 (1.0)	16218 (99.0)	
weeks)				
Any Underlying Medical Con	ditions			
Infant ^e				

Yes	1327	21 (1.6)	1306 (98.4)	0.02
No	16865	152 (0.9)	16713 (99.1)	
Maternal ^e				
Yes	10320	91 (0.9)	10229 (99.1)	0.001
No	7872	82 (1.0)	7790 (99.0)	

^a Unadjusted chi-square and fisher's exact test p-values of ≤ 0.05 were considered statistically significant. ^b Race/Ethnicity was extracted from medical records.

^c Maternal COVID-19 diagnosis was based on a recorded COVID-19 diagnosis (ICD-10: U07.1) or a recorded visit with confirmed SARS-CoV-2 infection by any method (RT-PCR, antigen, etc.) based on hospital records at any time during the pregnancy or during the six months after delivery.

^d Gestational age at delivery (preterm [<37 weeks], term [37-42 weeks], or post-term [>42 weeks]) was determined using reported gestational age at delivery or derived based on delivery date and estimated date of conception.

^e Definition of any underlying medical conditions for mothers and infants can be found in Appendix.

Table 2. Incidence rates^a per 1,000 person-weeks of medically attended COVID-19 episodesamong infants under 6 months of age born to mothers in the eESPI cohort, Epidemiology ofSARS-CoV-2 in Pregnancy and Infancy (ESPI) Network: Electronic Cohort (eESPI) (N=173).

	Infants with	Person-Weeks ^b	Incidence Rates per 1,000
	Medically		Person-Weeks, 95% CI
	Attended		
	COVID-19		
	Episodes		
Characteristics			
Overall incidence rate	173	307059.86	0.6 (0.5 - 0.6)
SARS-CoV-2			
<i>Circulation</i> ^c			
Low	90	188198.86	0.4 (0.3 – 0.5)
High	83	111843.71	0.6 (0.5 – 0.8)
Infant Age ^d			
Under 1 month	27	67648.00	2.0 (1.7 – 2.5)
1 month	29	58250.57	2.0 (1.6 - 2.4)
2 months	28	50772.86	1.6 (1.3 – 2.1)
3 months	16	45530.00	1.3 (0.9 – 1.8)
4 months	31	40628.14	1.2 (0.8 – 1.7)
5 months	42	36421.71	0.7 (0.4 – 1.2)
Infant Sex			

Male	93	158088.57	0.5 (0.4 - 0.6)
Female	80	148922.00	0.5 (0.4 - 0.6)
Maternal Race/Ethnicity ^e			
Non-Hispanic White	32	129786.29	0.2 (0.1 – 0.3)
Non-Hispanic Black	25	28971.43	0.9 (0.6 – 1.4)
Hispanic	81	82956.29	0.9 (0.7 – 1.1)
Other	30	59839.57	0.3 (0.2 – 0.5)
Unknown	5	5506.29	0.6 (0.3 – 1.5)
Maternal Medicaid			
Yes	51	64885.86	0.8 (0.6 – 1.1)
No	120	239298.14	0.4 (0.3 – 0.5)
Unknown	2	2875.86	0.6 (0.1 – 2.2)
Maternal COVID-19			
Diagnosis ^f			
During Pregnancy	6		0.5 (0.2 – 1.5)
only		6761.43	
During Post-partum	99		12.5 (9.8 – 16.0)
Period		7412.00	
During Pregnancy and	2		1.6 (0.4 – 6.3)
Post-partum Period		1187.57	
No known COVID-	66		0.2 (0.2 - 0.3)
19		291698.86	

Any Underlying Medical

Conditions

Infant^g

Yes	21	24417.29	0.7 (0.4 – 1.1)
No	152	282642.57	0.5 (0.4 - 0.6)
Maternal ^h			
Yes	91	174994.14	0.5 (0.4 - 0.6)
No	82	132065.71	0.5 (0.4 - 0.6)

^a Overall incidence rate is a crude aggregate incidence rate. Incidence rates by circulation period and infant and maternal characteristics are site-adjusted.

^b Person-week for all infants <6 months of age born to mothers in the eESPI cohort.

^c High and low SARS-CoV-2 circulation weeks were defined for each site as weeks with case counts above the median case count (high) or below the median case count (low) for the study period, using Health and Human Services (HHS) representative county-level surveillance data for Texas (Harris County), Oregon (Multnomah County), and California (Santa Clara County) in each health system's service area (HHS 2021).

^d Infant age was defined as 0-30 days (< 1 month old); 31-60 days (1 month); 61-90 days (2 months); 91-120 days (3 months); 121-150 (4 months); 151-185 days (5 months).

^e Race/Ethnicity was extracted from medical records.

^f Medically attended maternal COVID-19 was based on a recorded COVID-19 diagnosis (ICD-10: U07.1) or a recorded visit with confirmed SARS-CoV-2 by any method (RT-PCR, antigen, etc.) based on hospital records at any time during the pregnancy or during the six months after delivery.

^g Infant age was defined as 0-30 days (< 1 month old); 31-60 days (1 month); 61-90 days (2 months); 91-120 days (3 months); 121-150 (4 months); 151-185 days (5 months).

^h Medically attended maternal COVID-19 was based on a recorded COVID-19 diagnosis (ICD-10: U07.1)

or a recorded visit with confirmed SARS-CoV-2 by any method (RT-PCR, antigen, etc.) based on hospital

records at any time during the pregnancy or during the six months after delivery.

Appendix A: Data Dictionary

Variable	ESPI Variable	Variable	ICD-10 Codes
, and the second		Description	
Medically	IN_COVID_CONF_VTST# OR	Confirmed SARS-	ICD-10: U07.1
Attended	IN_ARFI_COVID	CoV-2 by any	
Infant COVID-		method for any	
19		test for neonate	
		OR Identifies	
		COVID-19	
		diagnosis code	
Medically	PR_COVID_CONF_VTST# OR	Confirmed SARS-	ICD-10: U07.1
Attended	PR_ARFI_COVID	CoV-2 by any	
Maternal		method for any	
COVID-19		test during	
during		pregnancy OR	
Pregnancy		Identifies	
		COVID-19	
		diagnosis code	
		during pregnancy	
Medically	PP_COVID_CONF_VTST# OR	Confirmed SARS-	ICD-10: U07.1
Attended	PP_ARFI_COVID	CoV-2 by any	
Maternal		method for any	
COVID-19		test OR Identifies	
post-partum		COVID-19	
		diagnosis code	
		post-partum	
Maternal	Calculated based on responses to	Maternal race and	No codes
Race/Ethnicity	PR_MAT_ETHNICITY AND	Maternal ethnicity	
	PR_MAT_RACE		
Maternal	PR_MAT_MEDICAID	Maternal status	No codes
Medicaid		for Medicaid	
		coverage	
Gestational	PR_PREG_GA_DEL_NEO# or if	Gestational age at	ESPI derived from
Age	blank calculated based on	delivery date	DELIVERY_DI_NEO#,
			FIKSI_US_DI,
	DD DELIVEDY DT NEO	Data of	GA_FIRS1_US
	PR_DELIVER I_DI_NEO	Date of	ansidered as End of
		Dragnanov	Dragnanay data in if the
		Freghancy	programov and in a way
			other then a delivery (ag
			other than a derivery (eg,
			the date of that outcome
			should be recorded under
			this variable
	PR FST CONCEPTION	Estimated date of	FSPI calculated from
		conception	EST DELIVERY
			EST_CONCEPTION -
			(EST_DELIVERY –
			280)

Infant	IN HR CONDITION PL	High risk medical	See appendix B.
Underlying		condition (chronic	
Conditions		condition, not	
		pregnancy	
		complication)	
Maternal	PR_HR_CONDITION_PL	High risk medical	See appendix B.
Underlying		condition (chronic	••
Conditions		condition, not	
		pregnancy	
		complication)	
Timing of	IF PR_COVID_CONF_VTST# OR		ICD-10: U07.1
Maternal	PR_ARFI_COVID then COVID		
COVID-19	during pregnancy.		
	IF PP_COVID_CONF_VTST# OR		ICD-10: U07.1
	PP_ARFI_COVID then		
	COVID-19 during post-partum.		
Infant	IN_HOSP_ADM_DT	Hospital	
Hospitalization		admission date	
Infant Death	INF_DEATH	Infant Death	
Live Birth	Calculated based on responses to	Stillborn infant	O60.1; O60.10; O60.12;
	PR_OUT_STILLBIRTH_NEO#	(infant born $>=20$	O60.13; O60.14; P07.21;
		weeks gestation	P07.22; P07.23; P07.24;
		with no sign of	P07.25; P07.26; P07.3;
		life) [multiple	P07.30; P07.31; P07.32;
		fetuses/neonates]	P07.33; P07.34; P07.35;
			P07.36; P07.37; P07.38;
			P07.39
	PR_PREG_GA_DEL_NEO#/	Gestational age at	Derived or extracted
	PREG_GA_DEL_EX_NEO/	delivery date	from Medical Records.
	PREG_GA_DEL_ANALYTIC_NE		
	O#		For Baylor:
			PREG_GA_DEL_ANAL
			YTIC_NEO# =
			PREG_GA_DEL_EX_N
			EO#
			For KPNW and KPNC:
			PREG_GA_DEL_ANAL
			YTIC_NEO# =
			PREG_GA_DEL_NEO#
	PR_OUT_ABORTION_NEO	Induced	Z33.2, O04.80.
		termination of	
	DD OUT DDETERNA NEO	pregnancy	
	PK_OUT_PKETERM_NEO	Preterm birth (A	060.1; 060.10; 060.12;
		live birth with an	060.13; 060.14; P07.21;
		estimated	P07.22; P07.23; P07.24;
		gestation < 37	P07.25; P07.26; P07.3;
		weeks) [multiple	P07.30; P07.31; P07.32;
		tetuses/neonates]	P07.33; P07.34; P07.35;

			P07.36; P07.37; P07.38;
		T 1 1 1	P07.39
	OUT_LIVEBIRTH_NEO	Live birth	
	PR_OUT_MISCARRIAGE_NEO		LCD 10, 150 01, 150 02
*NAC = Non- Acute: AC =	IN_HR_AC_HEAR1_FAIL_VL	(Acute of chronic) heart failure diagnosis	ICD-10: I50.21, I50.23, I50.31, I50.33, I50.41, I50.43
Acute	IN_HR_AC_HEART_VL	Acute heart disease diagnosis	ICD-10: I40, J10.82, J11.82, I30, I31.4, R57.0, I50.21, I50.23, I50.31, I50.33, I50.41, I50.43, I50.811, I50.813, I16, I10, I11, I11.9, I11.0, I15, I15.0, I15.9, I16.0, I16.1, I16.9, I20.0, I21, I21.0, I21.1, I21.2, I21.3, I21.4, I21.9, I22, I22.0, I22.1, I22.2, I22.8, I22.9, I24
	IN_HR_CARD_ARRST_VL	Cardiac arrest diagnosis	ICD-10: I46.9
	IN_HR_HEART_FAIL_VL	(Acute or chronic) heart failure diagnosis	ICD-10: I50
	IN_HR_NAC_HEART_VL	Non-acute heart disease diagnosis	ICD-10: A52.0, H35.031- 039, I01, I09.2, I05-08, I34, I35, I36, I37, I09, I12, I13, I23, 125-28, I33, I31 (except I31.4), I38, I39, I42-44, I46, I47, I48, I49, I50.1, I50.9, I41, I51, I52, I70, I71, I72, I73, I74, I75, M30.0, M31, I77, I79, I97.0, I97.1, Q21-27, T82, Z95, Q20, Q27.0, Q27.3, Q27.4, Q27.8, Q27.9, Q28, Q89.3, R00.1, Z98.61, Z79.82
Infant Liver *NAC = Non- Acute; AC =	IN_HR_LIVER_VL	(Acute or chronic) Liver disease diagnosis	ICD-10: K70, K73, K74, K75.1-K75.9, I85, K71, K72, K75, K76, K77
Acute	IN_HR_NAC_LIVER_FAIL_VL	(Non-acute) liver failure diagnosis	ICD-10: K72.1, K76.2
	IN_HR_AC_LIVER_FAIL_VL	Acute liver failure diagnosis	ICD-10: K72.0, K76.3
Infant Lung	IN_HR_OLUNG_VL	Lung disease diagnosis, not asthma	ICD-10: A15, A17, A18, A19, A31, D86, E84, J40, J41, J42, J43, J47, J60, J61, J62.0, J62.8, J63.6, J64, J67, J68, J69.0, J69.1, J69.8, J70.9,

	J85, J93, J98, M34, M35,
	Q34, R09.1, A31.0, B39,
	B40,, B41, B44, B45,
	B46.0, D86.0, E88.01,
	J62, J63, J65, J66, J69,
	J70, J82, J84, J86, J95.0,
	J96, J98.1, J99, P25, P26,
	P27, P28, Q33, T86.8,
	J44

Appendix B: List of High-Risk Medical Conditions

This set of variables looks at whether each participant had different high-risk medical conditions in diagnosis codes across every visit or admission within the time window for the pull. Each visit or admission for the participant will be evaluated for whether it included one of the listed ICD-10 codes. If any visit/admission for the participant across the entire time window did include one of the ICD-10 codes in question, the variable will be equal to 1 (One or more codes listed). If not, the variable will be equal to 0 (No code listed).

ESPI Variable	Variable Description	ICD-19 Codes
IN_HR_EXCLD_ANEMIA_PL ^a	High risk medical condition (chronic condition, not pregnancy complication) for Infant excluding Anemia	Presence of any of the conditions listed below.
PR_HR_EXCLD_ANEMIA_PL ^b	High risk medical condition (chronic condition, not pregnancy complication) for Mother during pregnancy excluding Anemia	Presence of any of the conditions listed below.
HR_BLOOD_PL	Blood disorder diagnosis	ICD-10: D50.0, D50.8, D50.9, D51, D52, D53, D55-61, D64.0-3, D63.1, D63.0, D63.8, D64.4, D64.8, D64.81, D64.89, D64.9, D66-75, D77

HR BLOOD EXCLD ANEMIA PL	Blood disorder	ICD-10: D56-61 D64 0-4 D64 8 D63 1 D63 0
	diagnosis (other	D63 8 D64 81 D66-75 D77
	than anemia)	
HR DIABT PL	Diabetes	ICD-10: E08-E11
	diagnosis	
HR_AC_HEART_FAIL_PL	Acute heart	ICD-10: I50.21, I50.23, I50.31, I50.33, I50.41,
	failure diagnosis	150.43
HR_HEART_FAIL_PL	(Acute or	ICD-10: I50
	chronic) heart	
	failure diagnosis	
HR_CARD_ARRST_PL	Cardiac arrest	ICD-10: I46.9
	diagnosis	
HR_AC_HEART_PL	Acute heart	ICD-10: I40, J10.82, J11.82, I30, I31.4, R57.0,
	disease diagnosis	150.21, 150.23, 150.31, 150.33, 150.41, 150.43,
		150.811, 150.813, 116, 110, 111, 111.9, 111.0, 115,
		115.0, 115.9, 116.0, 116.1, 116.9, 120.0, 121, 121.0,
		122.2, 122.8, 122.9, 124
HR_NAC_HEART_PL	Non-acute heart	ICD-10: A52.0, H35.031-039, 101, 109.2, 105-08,
	disease diagnosis	134, 135, 130, 137, 109, 112, 113, 123, 125-28, 135, 121 (avagent 121.4), 128, 120, 142, 44, 146, 147, 148
		131 (except 131.4), 138, 139, 142-44, 140, 147, 148, 140, 150, 1, 150, 0, 141, 151, 152, 170, 171, 172, 173
		149, 150.1, 150.9, 141, 151, 152, 170, 171, 172, 173, 174, 175, M30.0, M31, 177, 179, 197.0, 197.1, 021
		27 T82 795 020 027 0 027 3 027 4 027 8
		027.9. 028. 089.3. R00.1. Z98.61. Z79.82
HR CANCER PL	Cancer diagnosis	ICD-10: C00, C01, C02, C07, C08, C03, C04,
	0	C05, C06, C09, C10, C11, C12, C13, C14, C15,
		C16, C17, C18, C19, C20, C21, C22, C23, C24,
		C25, C48, C26, C30, C31, C32, C33, C34, C38,
		C37, C39, C40, C41, C44, C49, C43, C50, C46,
		C55, C53, C58, C54, C56, C51, C52, C61, C62,
		C60, C67, C64, C69, C71, C72, C73, C74, C75,
		C76, C77, C78, C79, C80, C81, C83, C90, C91,
		C92, C93, C94, C95, C7A, D02, D37-44, D48,
		Z51.11, Z51.12, C47, C4A, C57, C65, C66, C68,
		C/0, C/B, D03, Z85, M36.0, Z51.0, Z51.1,
		C95.00, C95.10, D61.0, D61.2, C82, C84, C85, C96, C98, C96, C96, C98, C96, C96, C96, C96, C96, C98, C96, C96, C96, C96, C96, C96, C96, C96
LID IMMUNE DI	Immuna disordar	Coo, Coo, Coo ICD 10: P20 P22 2 P50 D72 C70.8 M22 10
III_IWIWIUNE_FL	diagnosis	M35 M05 M06 R82 8 R84 7 R85 7 R87 7
	diagnosis	R89 7 T45 Z21 Z94 B97 3 D47 Z1 D76 M07
		M35.0, M35.9, 089.0, T45.1X1, T86.1, T86.2
		T86.3, T86.4, T86.81, T86.85, Z48.2, Z94.0,
		294.1, 294.2, 294.3, 294.4, 294.82, 294.83,
		Z94.84, T86.0, T86.5, D80, D81, D82, D83, D84,
		D89, D89.81, M08, L40, M32, M30, M33, D46,
		Z79.5, Z79.52, B97.35, O98.7, D61.9, D73.0
HR_AC_RENAL_FAIL_PL	Acute renal failure diagnosis	ICD-10: N17, N01
HR_NAC_RENAL_FAIL_PL	(Non-acute)	ICD-10: I13.11, I13.2, K76.7, D63.1, I12.0,
	Renal failure	I13.11, I13.2, N03, N04, N18, N19, N26.9,
	diagnosis	N25.0, N25.1, N27.0, N27.1, N27.9, N28.89,
		Q61, Z49, Z91.15, N02, N06, N07, N08, N11,
		N14, N15, N16, N25, N26, N28, Q27.1, Q27.2,
		Q60, Z99.2

	A (1'	
HR_AC_LIVER_FAIL_PL	failure diagnosis	ICD-10: K/2.0, K/6.3
HR_NAC_LIVER_FAIL_PL	(Non-acute) liver failure diagnosis	ICD-10: K72.1, K76.2
HR_LIVER_PL	(Acute or chronic) Liver disease diagnosis	ICD-10: K70, K73, K74, K75.1-K75.9, I85, K71, K72, K75, K76, K77
HR_ASTHMA_PL	Asthma diagnosis	ICD-10: J45
HR_OLUNG_PL	Lung disease diagnosis, not asthma	ICD-10: A15, A17, A18, A19, A31, D86, E84, J40, J41, J42, J43, J47, J60, J61, J62.0, J62.8, J63.6, J64, J67, J68, J69.0, J69.1, J69.8, J70.9, J85, J93, J98, M34, M35, Q34, R09.1, A31.0, B39, B40,, B41, B44, B45, B46.0, D86.0, E88.01, J62, J63, J65, J66, J69, J70, J82, J84, J86, J95.0, J96, J98.1, J99, P25, P26, P27, P28, Q33, T86.8, J44
HR_OBESE_PL	Obesity diagnosis	ICD-10: E66, O99.210-215, O99.840-845, Z68.4
HR_SEV_OBESE_PL	Severe (morbid) obesity dx	ICD-10: E66.01
HR_OMETBOL_PL	Metabolic disorder diagnosis not obesity	ICD-10: E03-E07, E22, E23, E32, E27, E40-E46, E50-E56, E70-E72, E74, E78, E88, M10, E83, E75.2, E76, E77, E79, E80, E85, E89.1, E89.6, E01, E20, E21, E24, E25, E26, E28, E31, E34
HR_ALT_MENT_PL	Altered mental status diagnosis	ICD-10: F05, F06.0, F06.1, F06.2, F06.30, F06.4, F06.8, G45.4, R40.0, R40.4, R41.82, R44.0, R41
HR_ENCEPHAL_PL	Encephalopathy diagnosis	ICD-10: G93.4, I67.4, K72.90, K72.91
HR_MENINGITIS_PL	Meningitis diagnosis	ICD-10: A02.21, A17.0, A39, A87.0, A87.1, B37.5, B38.4, G00, G01, G02, G03
HR_ANOX_BRN_DMG_PL	Anoxic brain damage diagnosis	ICD-10: G93.1
HR_ENCEPH_MYEL_PL	Encephalitis or myelitis diagnosis	ICD-10: A39.81, G05, G37.3
HR_COMA_PL	Coma diagnosis	ICD-10: R40.20, R40.3
HR_POLYNEURO_PL	Critical illness polyneuropathy diagnosis	ICD-10: G62.81
HR_CEREBRAL_INFARC_PL	Cerebral infarction diagnosis	ICD-10: G43.6, I63.019, I63.119, I63.139, I63.20, I63.219, I63.22, I63.239, I63.30, I63.40, I63.50, I63.59
HR_CEREBRAL_HEMR_PL	Cerebral hemorrhage diagnosis	ICD-10: I60.9, I61.9, I62
HR_CEREBRAL_EDEMA_PL	Cerebral edema diagnosis	ICD-10: G93.6
HR_NEURO_PL	Acute or Chronic Neurologic disease diagnosis	ICD-10: A17, A81, B90.0, F01, F02, F03, F07, F71, F72, F73, E75, G20, G25, G26, G11, M47, G60, G35, G36, G81, G80, G82, G40, G93, G96, I02, I60, I61, I62, I65, I66, I67.82, I67.9, I69, G71.13, R56, T85, I68, A17.0, E75.02, E75.19, E75.4, F84.2, G10, G12-14, G21, G23, G24, G30, G31, G32, G37, G45, G46, G63, G64, G70, G71, G73, G83, G90.3, G91, G94, G95, G99.2,

		1140.81 005 076 70 085 087 4 000 02 006
		R41, R53.2, R54
HR_AC_NEURO_PL	Only Acute	ICD-10: G04.0, I63, I67.81, I67.82, G45, G45.4,
	Neurologic	G36, G04, G05, G61.0, I60-I62, G00-G03
	disease diagnosis	
HR_ART_VEN_EMBOL_PL	Arterial or	ICD-10: I74, I76, I82
	venous embolism	
	diagnosis	
HR_AC_ENDOCRINE_PL	Acute endocrine	ICD-10: E08.1, E08.10, E08.11, E09.1, E09.10,
	complications	E09.11, E10.1, E10.10, E10.11, E11.1, E11.10,
		E11.11, E13.1, E13.10, E13.11, E08.0, E08.00,
		E08.01, E09.0, E09.00, E09.01, E11.0, E11.00,
		E11.01, E13.0, E13.00, E13.01, E05
HR_AC_GASTRO_PL	Acute	ICD-10: K72.0, B15, B16, B17, B19.0, B19.11,
	gastrointestinal	B19.21, K85, J09.X3, J10.2, J11.2
	complications	
HR_AC_HEMATO_PL	Acute	ICD-10: D65, I82.210, I82.290, I82.220, I82.4,
	hematological	182.6, 182.A1, 182.B1, 182.C1, D76.1, D76.2,
	complications	D69.3, 126, D57.0, D57.01, D57.02, D57.21,
		D57.211, D57.212, D57.41, D57.411, D57.412,
	D 1	D57.81, D57.811, D57.812
HR_PULM_EMBOL_PL	Pulmonary	ICD-10: 126
	diagnosia	
LID CADDITIS DI	Carditia diagnosia	ICD 10: A 20 50 D27 6 101 0 101 1 101 2 120
HK_CARDITIS_PL	Carditis diagnosis	ICD-10: A59.50, B57.0, 101.0, 101.1, 101.2, 150,
HR DIC PI	Defibrination	ICD 10: D65
	syndrome	ICD-10. D05
	diagnosis	
HR KETOACIDOSIS PL	Ketoacidosis	ICD-10: E08.1, E10.1, E13.1
	diagnosis	
HR HYPRSMOLRTY PL	Hyperosmolarity	ICD-10: E08.0, E11.0, E13.0
	diagnosis	
HR_DIABET_COMA_PL	Diabetic coma	ICD-10: E08.11, E08.641, E09.11, E09.641,
	diagnosis	E10.11, E11.01, E11.641, E13.11, E13.641, E15
HR_THYRD_STORM_PL	Thyroid storm	ICD-10: E05.01, E05.11, E05.21, E05.31, E05.41,
	diagnosis	E05.81, E05.91
HR_RHABDOMYOL_PL	Rhabdomyolisis	ICD-10: M62.82
	diagnosis	
HR_MYOSITIS_PL	Myositis	ICD-10: M60
	diagnosis	
HR_MYOPATHY_PL	Critical illness	ICD-10: G72.81
	myopathy	
	diagnosis	ICD 10, 706 22
HR_GEST_DIABT_PL	History of	ICD-10: Z86.32
	diabetes	
HR CHRONHTN P	Dregnancy	ICD 10: 010 (010.0 010.00) 011 (011.1
IK_CIKONITIN_FL	complicated by	(011.0)
	preevisting	011.7)
	hypertension with	
	or without	
	preeclampsia	
HR PREECL PL	Preeclampsia	ICD-10: 014 (014.0–014.05). 014 1 (014 10–
	diagnosis during	014.15), 014.2 (014.20-014.25), 015 (015.0-

	pregnancy or postpartum, with or without severe features, and including	O15.9), O14.9 (O14.90 – O14.95), O11 (O11.1- O11.9)
	preeclampsia	
HR_PRCLSEVERE_PL	Preeclampsia with severe features	ICD-10: O14.1 (O14.10– O14.15), O14.2 (O14.20-O14.25), O15 (O15.0-O15.9)
HR_HELLP_PL	HELLP syndrome	ICD-10: O14.2 (O14.20-O14.25)
HR_GESTHTN_PL	Gestational hypertension (new onset) without proteinuria	ICD-10: O13 (O13.0-O13.9)

Any underlying medical conditions for the infant included any blood disorder, diabetes, acute or chronic heart failure diagnosis, cardiac arrest, acute or chronic heart disease (congenital), cancer, immune disorder, acute or non-acute renal failure, acute or non-acute liver failure, liver disease, asthma, lung disease (not asthma), altered mental status, encephalopathy, meningitis, anoxic brain damage, encephalitis or myelitis, coma, critical illness polyneuropathy, cerebral infarction, cerebral hemorrhage, cerebral edema, acute or chronic neurologic disease, arterial or venous embolism diagnosis, acute endocrine complications, acute gastrointestinal complications, acute hematological complications, pulmonary embolism, carditis, defibration syndrome, ketoacidosis, hyperosmolarity, diabetic coma, thyroid storm, rhabdomyolysis, myositis, or critical illness myopathy. For pregnant women/mothers, additional conditions included history of gestational diabetes, pregnancy complicated by preexisting hypertension with or without preeclampsia, preeclampsia diagnosis during pregnancy or postpartum, with or without severe features, and including superimposed preeclampsia, preeclampsia with severe features, HELLP syndrome, or gestational hypertensions (new onset) without proteinuria.